Stockscreener 앱 받기
1.88
5.03%
0.09
시간 외 거래:
1.82
-0.06
-3.19%
Marker Therapeutics Inc 주식(MRKR)의 최신 뉴스
Marker Therapeutics Announces Board Resignation - MSN
MRKR stock touches 52-week low at $1.8 amid market challenges - MSN
Marker Therapeutics Announces Board Resignation By Investing.com - Investing.com Nigeria
Marker Therapeutics pops on receiving $9.5M grant to advance lead asset - MSN
Hematopoietic Stem Cell Transplantation Market: Soaring - openPR
MRKR stock touches 52-week low at $2.4 amid challenging year - MSN
MRKR stock touches 52-week low at $2.4 amid challenging year By Investing.com - Investing.com South Africa
Marker Therapeutics (NASDAQ:MRKR) Shares Down 7.5% – What’s Next? - Defense World
SEC Form 424B3 filed by Marker Therapeutics Inc. - Quantisnow
BostonGene Evaluates Novel Therapies and Immune System Profiling as a Marker of Response in Patients with Gastrointestinal Cancers - Business Wire
BioZorb Lawuit LawyerBreast Biopsy Marker RecallJanuary 2025 Update - Levin Papantonio
MRKRMarker Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Marker Therapeutics director Steve Elms acquires $35,472 in stock By Investing.com - Investing.com Australia
Marker Therapeutics director Steve Elms acquires $35,472 in stock - Investing.com India
Sterling Bank shareholders approve its buyout by EverBank - Jacksonville Daily Record
Marker Therapeutics sees $1.77 million stock acquisition by investors By Investing.com - Investing.com Australia
Marker Therapeutics, Inc. announced that it expects to receive $16.1 million in funding - Marketscreener.com
Marker Therapeutics sells 5.03M shares at $3.20 in private placement - MSN
Marker Therapeutics reports promising lymphoma study results By Investing.com - Investing.com UK
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - GlobeNewswire
Marker Therapeutics Announces $16.1 Million Private Placement - GlobeNewswire
Marker Therapeutics Secures $16.1M Private Placement to Advance Lymphoma Cell Therapy Trial - StockTitan
Marker Therapeutics' MT-601 Shows 78% Response Rate in Lymphoma Trial, Promising Post-CAR-T Results - StockTitan
Marker Therapeutics pops on receiving $9.5M grant to advance lead asset (NASDAQ:MRKR) - Seeking Alpha
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer - The Manila Times
Marker Therapeutics receives $9.5 million grant for study - Investing.com
Marker Therapeutics Awarded $9.5 Million Grant from the - GlobeNewswire
Marker Therapeutics Secures $9.5M Grant to Advance Promising Pancreatic Cancer Treatment - StockTitan
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium - The Manila Times
Marker Therapeutics to Present at the 2024 Ladenburg - GlobeNewswire
Marker Therapeutics CEO to Present Latest Immunotherapy Innovations at Ladenburg Thalmann Oncology Symposium - StockTitan
Marker Therapeutics Leads 3 Noteworthy US Penny Stocks - Simply Wall St
Baylor College of Medicine-partnered Marker Therapeutics files for $11.4M offering - The Business Journals
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit - GlobeNewswire
Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study - MSN
Hematopoietic Stem Cell Transplantation Market to Exhibit - openPR
Silence Therapeutics' Zerlasiran Shows 90% Reduction in Key Heart Disease Marker | SLN Stock News - StockTitan
Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
4.02%
0.32%
자본화:
|
볼륨(24시간):